Value proposition

Investing Where Biology and Technology Converge

Genoa Ventures invests in early-stage companies innovating at the convergence of biology and technology.

Visionary startups developing innovative life science technologies with outsized potential often struggle to raise capital from traditional funders. These companies are typically multi-disciplinary (e.g. genomics + optics + microfluidics + big data) and/or market-making, and don't neatly fit most VC’s patterns and boxes.

Genoa Ventures stands in this gap. Genoa Ventures uniquely combines an appetite for technology-driven, “category-defying” opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early, before most other investors. We take the time to understand the science and technology, applications and markets, and to help these companies achieve their full potential.

We believe in the enormous and relatively untapped possibilities of life science technologies and discoveries applied to realms outside of healthcare, and in the unbounded potential of the entrepreneurial visionaries who will lead us in realizing these possibilities.

synthetic biology, genomics, genetics, research tools, venture capital, Seed, Series A, diagnostics, agriculture, go-to-market strategy, and cytometry